Coming from the nano perspective, the challenge right now is that the different agencies don't know how to regulate it. Do you regulate it as a drug, or do you regulate it as a device? I work with both the U.S. FDA as well as Health Canada and they are trying to figure it out. Right now it's actually considered a special case, based on a case-by-case basis. That's one challenge.
The second challenge is information. We're developing ways to detect genomics. Is it too much information? There are ethics associated with it. We know that somebody has certain genetic predispositions. Especially when you're using a point-of-care device, how does that affect the person who is actually doing the analysis? Facebook and social media have changed the way we look at communication, so technology is improving the way we are communicating. If you can look in your own iPhone and find out that you have a genetic predisposition for genetics A, B, C, and D, what are you going to do with that information? That's what we're left with at this point.
It's an ethical issue from that perspective.